Hikma Pharmaceuticals Plc (LON:HIK) was downgraded by equities research analysts at Morgan Stanley to an “equal weight” rating in a report released on Monday. They presently have a GBX 1,350 ($17.53) target price on the stock, down from their prior target price of GBX 1,600 ($20.77). Morgan Stanley’s target price would suggest a potential upside of 4.81% from the company’s previous close.

Other equities analysts have also issued reports about the stock. Numis Securities Ltd reissued an “add” rating and issued a GBX 2,000 ($25.96) price objective on shares of Hikma Pharmaceuticals Plc in a research report on Friday, May 19th. Peel Hunt reissued a “hold” rating and issued a GBX 2,150 ($27.91) price objective on shares of Hikma Pharmaceuticals Plc in a research report on Thursday, August 17th. Jefferies Group LLC dropped their price objective on shares of Hikma Pharmaceuticals Plc from GBX 1,390 ($18.04) to GBX 1,045 ($13.57) and set a “hold” rating on the stock in a research report on Monday. J P Morgan Chase & Co reissued a “neutral” rating and issued a GBX 1,500 ($19.47) price objective (down from GBX 1,800 ($23.37)) on shares of Hikma Pharmaceuticals Plc in a research report on Monday, May 22nd. Finally, Citigroup Inc. reissued a “neutral” rating and issued a GBX 1,550 ($20.12) price objective on shares of Hikma Pharmaceuticals Plc in a research report on Wednesday, June 28th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of GBX 1,686 ($21.89).

Hikma Pharmaceuticals Plc (LON HIK) traded up 4.12% during trading on Monday, reaching GBX 1288.00. 939,312 shares of the company’s stock were exchanged. Hikma Pharmaceuticals Plc has a 1-year low of GBX 1,101.00 and a 1-year high of GBX 2,346.00. The company’s 50-day moving average is GBX 1,346.92 and its 200-day moving average is GBX 1,734.37. The company’s market capitalization is GBX 3.09 billion.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/21/hikma-pharmaceuticals-plc-hik-cut-to-equal-weight-at-morgan-stanley.html.

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals Plc (LON:HIK)

Receive News & Stock Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related stocks with our FREE daily email newsletter.